PRVCF Quote, Financials, Valuation and Earnings

CeCors, Inc. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of --. PreveCeutical Medical, Inc.'s return on equity of -- beat CeCors, Inc.'s return on equity of --.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CeCors, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that PreveCeutical Medical, Inc. has higher upside potential than CeCors, Inc., analysts believe PreveCeutical Medical, Inc. is more attractive than CeCors, Inc..

PreveCeutical Medical, Inc. has a beta of 0.752, which suggesting that the stock is 24.825% less volatile than S&P 500. In comparison CeCors, Inc. has a beta of -0.003, suggesting its less volatile than the S&P 500 by 100.33%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CeCors, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. CeCors, Inc. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are larger than CeCors, Inc. quarterly revenues of --. PreveCeutical Medical, Inc.'s net income of -$623K is higher than CeCors, Inc.'s net income of --. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while CeCors, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus 0.70x for CeCors, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Hear AtLast Holdings, Inc. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of -5751.92%. PreveCeutical Medical, Inc.'s return on equity of -- beat Hear AtLast Holdings, Inc.'s return on equity of --.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Hear AtLast Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that PreveCeutical Medical, Inc. has higher upside potential than Hear AtLast Holdings, Inc., analysts believe PreveCeutical Medical, Inc. is more attractive than Hear AtLast Holdings, Inc..

PreveCeutical Medical, Inc. has a beta of 0.752, which suggesting that the stock is 24.825% less volatile than S&P 500. In comparison Hear AtLast Holdings, Inc. has a beta of 0.395, suggesting its less volatile than the S&P 500 by 60.537%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hear AtLast Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. Hear AtLast Holdings, Inc. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are smaller than Hear AtLast Holdings, Inc. quarterly revenues of $5.2K. PreveCeutical Medical, Inc.'s net income of -$623K is lower than Hear AtLast Holdings, Inc.'s net income of -$299.1K. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while Hear AtLast Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus 22.93x for Hear AtLast Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of --. PreveCeutical Medical, Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.07 which suggests that it could grow by 514.22%. Given that Oncolytics Biotech, Inc. has higher upside potential than PreveCeutical Medical, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than PreveCeutical Medical, Inc..

PreveCeutical Medical, Inc. has a beta of 0.752, which suggesting that the stock is 24.825% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.983, suggesting its less volatile than the S&P 500 by 1.711%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. PreveCeutical Medical, Inc.'s net income of -$623K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of -- compared to PreveCeutical Medical, Inc.'s net margin of -163.68%. PreveCeutical Medical, Inc.'s return on equity of -- beat Venus Concept, Inc.'s return on equity of -1236.95%.

PreveCeutical Medical, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 37451.12%. Given that Venus Concept, Inc. has higher upside potential than PreveCeutical Medical, Inc., analysts believe Venus Concept, Inc. is more attractive than PreveCeutical Medical, Inc..

PreveCeutical Medical, Inc. has a beta of 0.752, which suggesting that the stock is 24.825% less volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.062, suggesting its less volatile than the S&P 500 by 106.188%.

PreveCeutical Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PreveCeutical Medical, Inc. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

PreveCeutical Medical, Inc. quarterly revenues are --, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. PreveCeutical Medical, Inc.'s net income of -$623K is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, PreveCeutical Medical, Inc.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PreveCeutical Medical, Inc. is -- versus 0.01x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.